The T1799A BRAF mutation is absent in cribriform-morular variant of papillary carcinoma

Archives of Pathology and Laboratory Medicine

Volumn 133, Issue 5, 2009, Pages 803-805

  Schuetze, David ^a   Hoschar, Aaron P ^a   Seethala, Raja R ^b   Assaad, Adel ^c   Zhang, Xiatong ^a   Hunt, Jennifer L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c VIRGINIA MASON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN; DNA;

ADENOMATOUS POLYP; ARTICLE; CARCINOGENESIS; CASE REPORT; DISEASE ASSOCIATION; GENE MUTATION; HUMAN; HUMAN TISSUE; THYROID PAPILLARY CARCINOMA; ADENOCARCINOMA; COLON POLYPOSIS; GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; POINT MUTATION; THYROID TUMOR;

ADENOCARCINOMA, PAPILLARY; ADENOMATOUS POLYPOSIS COLI; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; HUMANS; POINT MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS;

EID: 65649094412     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Harach HR, Williams GT, Williams ED. Familial adenomatous polyposis associated thyroid carcinoma: a distinct type of follicular cell neoplasm. Histo- pathology. 1994;25:549-561.
2. Cameselle-Teijeiro J, Chan JK. Cribriform-morular variant of papillary carcinoma: a distinctive variant representing the sporadic counterpart of familial adenomatous polyposis-associated thyroid carcinoma? Mod Pathol. 1 999;12: 400-411.
3. Sugg SL, Zheng L, Rosen IB, et al. Ret/PTC-1, -2, and -3 oncogene rearrangements in human thyroid carcinomas: implications for metastatic potential? J Clin Endocrinol Metab. 1996;81:3360-3365.
4. Cetta F, Pelizzo MR, Curia MC, Barbarisi A. Genetics and clinicopatholog- ical findings in thyroid carcinomas associated with familial adenomatous polyposis. Am J Pathol. 1999;155:7-9.
5. Soravia C, Sugg S, BerkT, et al. Familial adenomatous polyposis-associated thyroid cancer. Am J Pathol 1999;154:127-135.
6. Xu B, Yoshimoto K, Miyauchi A, et al. Cribriform-morular variant of papillary thyroid carcinoma: a pathological and molecular genetic study with evidence of frequent somatic mutations in exon 3 of the beta-catenin gene. J Pathol. 2003;199:58-67.
7. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer. 2005;12:245-262.
8. Hilger RA, Scheulen ME, Strumberg D. The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie. 2002;25:511-518.
9. Vojtek AB, Channing JD. Increasing complexity of the Ras signaling pathway. J Biol Chem. 1998;273:19925-19928.
10. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-954.
11. Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst. 2003;95:625-627.
12. Fukushima T, Suzuki S, Mashiko M, et al. BRAF mutations in papillary carcinomas of the thyroid. Oncogene. 2003;22:6455-6457.
13. Kimura ET, Nikiforova MN, Zhu Z, et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/ PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003;63:1454-1457.
14. Soares P, Trovisco V, Rocha AS, et al. BRAF mutations typical of papillary thyroid carcinoma are more frequently detected in undifferentiated than in insular and insular-like poorly differentiated carcinomas. Virchows Archiv. 2003;444:572-576.
15. Frattini M, Ferrario C, Bressan P, et al. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene. 2003;23:7436-7440.
16. Namba H, Nakashima M, Hayashi T, et al. Clinical implication ofhotspot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab.2003;88:4393-4397.
17. Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003;88:5399-5404.
18. Kim KH, Kang DW, Kim SH, et al. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J. 2004;45:818-821.
19. Xing M, Westra WH, Tufano R, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. JClin Endocrinol Metab. 2005;90: 6373-6379.